NasdaqGS:EPZM

Stock Analysis Report

Executive Summary

Epizyme, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States.

Snowflake

Fundamentals

Flawless balance sheet with high growth potential.

Share Price & News

How has Epizyme's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

19.3%

NasdaqGS:EPZM

-0.03%

US Biotechs

-1.0%

US Market


1 Year Return

30.0%

NasdaqGS:EPZM

-8.1%

US Biotechs

-0.4%

US Market

EPZM outperformed the Biotechs industry which returned -8.1% over the past year.

EPZM outperformed the Market in United States of America which returned -0.4% over the past year.


Share holder returns

EPZMIndustryMarket
7 Day19.3%-0.03%-1.0%
30 Day7.8%-0.1%-3.3%
90 Day20.0%3.1%0.8%
1 Year30.0%30.0%-7.3%-8.1%1.9%-0.4%
3 Year68.1%68.1%9.8%6.0%39.4%30.4%
5 Year-59.1%-59.1%8.1%3.1%54.2%37.1%

Price Volatility Vs. Market

How volatile is Epizyme's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Epizyme undervalued based on future cash flows and its price relative to the stock market?

4.33x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Epizyme to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Epizyme to establish if it is available at substantial discount.


Price Based on Earnings

Epizyme is loss making, we can't compare its value to the US Biotechs industry average.

Epizyme is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Epizyme, we can't assess if its growth is good value.


Price Based on Value of Assets

Epizyme is overvalued based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is Epizyme expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

46.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Epizyme's revenue is expected to grow significantly at over 20% yearly.

Epizyme's earnings are expected to grow significantly at over 20% yearly.

Epizyme's revenue growth is expected to exceed the United States of America market average.

Epizyme's earnings growth is expected to exceed the United States of America market average.

Epizyme's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Epizyme will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.


Next Steps

Past Performance

How has Epizyme performed over the past 5 years?

-15.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Epizyme does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Epizyme's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Epizyme's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Epizyme has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Epizyme has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Epizyme improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Epizyme's financial position?


Financial Position Analysis

Epizyme is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Epizyme's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Epizyme has no debt.

Epizyme has not taken on any debt in the past 5 years.


Balance Sheet

Low level of unsold assets.

Epizyme has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Epizyme has sufficient cash runway for 2.5 years based on current free cash flow.

Epizyme has sufficient cash runway for 2.3 years if free cash flow continues to grow at historical rates of 13.5% each year.


Next Steps

Dividend

What is Epizyme's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Epizyme's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Epizyme's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Epizyme has not reported any payouts.

Unable to verify if Epizyme's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Epizyme has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Epizyme's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Epizyme's salary, the management and board of directors tenure and is there insider trading?

1.2yrs

Average management tenure


CEO

Rob Bazemore (51yo)

3.9yrs

Tenure

US$3,650,871

Compensation

Mr. Robert B. Bazemore, Jr., also known as Bob, has been the Chief Executive Officer and President at Epizyme, Inc. since September 10, 2015 and serves as its Secretary. Mr. Bazemore served as the Chief Op ...


CEO Compensation Analysis

Rob's remuneration is about average for companies of similar size in United States of America.

Rob's compensation has increased whilst company is loss making.


Management Age and Tenure

1.2yrs

Average Tenure

51.5yo

Average Age

The average tenure for the Epizyme management team is less than 2 years, this suggests a new team.


Board Age and Tenure

6.9yrs

Average Tenure

61yo

Average Age

The tenure for the Epizyme board of directors is about average.


Insider Trading

Epizyme individual insiders have only sold shares in the past 3 months, but not in substantial volumes.


Recent Insider Transactions

SellUS$652,13428 Jun 19
New Enterprise Associates
EntityCompany
Shares52,473
Max PriceUS$12.43
SellUS$1,372,82526 Jun 19
New Enterprise Associates
EntityCompany
Shares104,944
Max PriceUS$13.31
SellUS$14,33914 Jun 19
Matthew Ros
EntityIndividual
Role
Chief Strategy & Business Officer
Shares1,185
Max PriceUS$12.10
BuyUS$3,750,00305 Oct 18
New Enterprise Associates
EntityCompany
Shares416,667
Max PriceUS$9.00

Ownership Breakdown


Management Team

  • Joseph Beaulieu (38yo)

    Controller

    • Tenure: 0.6yrs
  • John Weidenbruch (58yo)

    General Counsel

  • Paolo Tombesi (55yo)

    Chief Financial Officer

  • Shefali Agarwal (45yo)

    Chief Medical Officer

    • Tenure: 1.2yrs
    • Compensation: $2.00m
  • Rob Bazemore (51yo)

    President

    • Tenure: 3.9yrs
    • Compensation: $3.65m
  • Jason Fredette

    Vice President of Investor Relations

  • Matt Ros (52yo)

    Chief Strategy & Business Officer

    • Compensation: $1.72m
  • Yi Zhang

    Scientific Co-Founder & Member of The Scientific Advisory Board

  • Andrea Edwards

    Head of Human Resources & Organizational Development

  • H. Horvitz

    Co-Founder & Chairman of the Scientific Advisory Board


Board Members

  • Chris Walsh (75yo)

    Member of the Scientific Advisory Board

  • George Daley

    Member of the Scientific Advisory Board

  • Carl Goldfischer (60yo)

    Independent Director

    • Tenure: 9.9yrs
    • Compensation: $198.92k
  • Beth Seidenberg (62yo)

    Independent Director

    • Tenure: 11.5yrs
    • Compensation: $193.90k
  • Dave Mott (54yo)

    Chairman

    • Tenure: 3.3yrs
    • Compensation: $242.08k
  • Rob Bazemore (51yo)

    President

    • Tenure: 3.9yrs
    • Compensation: $3.65m
  • Bruce Chabner (78yo)

    Member of the Scientific Advisory Board

  • Yi Zhang

    Scientific Co-Founder & Member of The Scientific Advisory Board

  • Joel Huff

    Member of the Scientific Advisory Board

  • H. Horvitz

    Co-Founder & Chairman of the Scientific Advisory Board

Company Information

Epizyme, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Epizyme, Inc.
  • Ticker: EPZM
  • Exchange: NasdaqGS
  • Founded: 2007
  • Industry: biotechnology
  • Sector: pharmaceuticals & biotech
  • Market Cap: US$1.249b
  • Shares outstanding: 91.04m
  • Website: Click here

Number of Employees


Location

  • Epizyme, Inc.
  • 400 Technology Square
  • 4th Floor
  • Cambridge
  • Massachusetts
  • 2139
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
EPZMNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMay 2013
EPEDB (Deutsche Boerse AG)YesCommon StockDEEURMay 2013

Biography

Epizyme, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The com ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/18 00:39
End of Day Share Price2019/08/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.